These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26729900)

  • 21. [Advances in the treatment of Duchenne muscular dystrophy].
    Ortez C; Natera de Benito D; Carrera García L; Expósito J; Nolasco G; Nascimento A
    Medicina (B Aires); 2019; 79 Suppl 3():77-81. PubMed ID: 31603849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac Myoediting Attenuates Cardiac Abnormalities in Human and Mouse Models of Duchenne Muscular Dystrophy.
    Atmanli A; Chai AC; Cui M; Wang Z; Nishiyama T; Bassel-Duby R; Olson EN
    Circ Res; 2021 Sep; 129(6):602-616. PubMed ID: 34372664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toward the correction of muscular dystrophy by gene editing.
    Olson EN
    Proc Natl Acad Sci U S A; 2021 Jun; 118(22):. PubMed ID: 34074727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Duchenne muscular dystrophy: CRISPR/Cas9 treatment.
    Mendell JR; Rodino-Klapac LR
    Cell Res; 2016 May; 26(5):513-4. PubMed ID: 26926391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Less is more: therapeutic exon skipping for Duchenne muscular dystrophy.
    Aartsma-Rus A; van Ommen GJ
    Lancet Neurol; 2009 Oct; 8(10):873-5. PubMed ID: 19713153
    [No Abstract]   [Full Text] [Related]  

  • 26. Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice.
    Kenjo E; Hozumi H; Makita Y; Iwabuchi KA; Fujimoto N; Matsumoto S; Kimura M; Amano Y; Ifuku M; Naoe Y; Inukai N; Hotta A
    Nat Commun; 2021 Dec; 12(1):7101. PubMed ID: 34880218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CRISPR/Cas correction of muscular dystrophies.
    Zhang Y; Nishiyama T; Olson EN; Bassel-Duby R
    Exp Cell Res; 2021 Nov; 408(1):112844. PubMed ID: 34571006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of rAAVrh.74.MHCK7.micro-dystrophin Gene Therapy Using Magnetic Resonance Imaging in Children With Duchenne Muscular Dystrophy.
    Willcocks RJ; Forbes SC; Walter GA; Sweeney L; Rodino-Klapac LR; Mendell JR; Vandenborne K
    JAMA Netw Open; 2021 Jan; 4(1):e2031851. PubMed ID: 33394000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic Delivery of Morpholinos to Skip Multiple Exons in a Dog Model of Duchenne Muscular Dystrophy.
    Maruyama R; Echigoya Y; Caluseriu O; Aoki Y; Takeda S; Yokota T
    Methods Mol Biol; 2017; 1565():201-213. PubMed ID: 28364245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric RNA/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of duchenne muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon.
    Surono A; Van Khanh T; Takeshima Y; Wada H; Yagi M; Takagi M; Koizumi M; Matsuo M
    Hum Gene Ther; 2004 Aug; 15(8):749-57. PubMed ID: 15319032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression.
    Wang Z; Kuhr CS; Allen JM; Blankinship M; Gregorevic P; Chamberlain JS; Tapscott SJ; Storb R
    Mol Ther; 2007 Jun; 15(6):1160-6. PubMed ID: 17426713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Mutation-specific treatments for Duchenne muscular dystrophy].
    Matsuo M; Takeshima Y
    Brain Nerve; 2009 Aug; 61(8):915-22. PubMed ID: 19697880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Nonsense readthrough therapy for Duchenne muscular dystrophy].
    Takeshima Y
    Rinsho Shinkeigaku; 2014; 54(12):1074-6. PubMed ID: 25672712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intraarterial delivery of naked plasmid DNA expressing full-length mouse dystrophin in the mdx mouse model of duchenne muscular dystrophy.
    Zhang G; Ludtke JJ; Thioudellet C; Kleinpeter P; Antoniou M; Herweijer H; Braun S; Wolff JA
    Hum Gene Ther; 2004 Aug; 15(8):770-82. PubMed ID: 15319034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy.
    Romero NB; Braun S; Benveniste O; Leturcq F; Hogrel JY; Morris GE; Barois A; Eymard B; Payan C; Ortega V; Boch AL; Lejean L; Thioudellet C; Mourot B; Escot C; Choquel A; Recan D; Kaplan JC; Dickson G; Klatzmann D; Molinier-Frenckel V; Guillet JG; Squiban P; Herson S; Fardeau M
    Hum Gene Ther; 2004 Nov; 15(11):1065-76. PubMed ID: 15610607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy.
    Rodino-Klapac LR; Janssen PM; Montgomery CL; Coley BD; Chicoine LG; Clark KR; Mendell JR
    J Transl Med; 2007 Sep; 5():45. PubMed ID: 17892583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The Emeritus Dinosaur's viewpoint - The road to hell of gene therapists is paved with POC].
    Kaplan JC
    Med Sci (Paris); 2015 Nov; 31 Spec No 3():41-4. PubMed ID: 26546933
    [No Abstract]   [Full Text] [Related]  

  • 38. Neuromuscular disease: CRISPR/Cas9 gene-editing platform corrects mutations associated with Duchenne muscular dystrophy.
    Wood H
    Nat Rev Neurol; 2015 Apr; 11(4):184. PubMed ID: 25752950
    [No Abstract]   [Full Text] [Related]  

  • 39. A CRISPR edit for heart disease.
    King A
    Nature; 2018 Mar; 555(7695):S23-S25. PubMed ID: 29517035
    [No Abstract]   [Full Text] [Related]  

  • 40. Gene Editing for Duchenne Muscular Dystrophy Using the CRISPR/Cas9 Technology: The Importance of Fine-tuning the Approach.
    Tremblay JP; Iyombe-Engembe JP; Duchêne B; Ouellet DL
    Mol Ther; 2016 Nov; 24(11):1888-1889. PubMed ID: 27916992
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.